Background Injecting drug use is an important risk factor for transmission of viral hepatitis, but detailed, transparent estimates of the scale of the issue do not exist. We estimated national, regional, and global prevalence and population size for hepatitis C virus (HCV) and hepatitis B virus (HBV) in injecting drug users (IDUs).
Introduction
Injecting drug use is an important public health issue around the world: 16 million people injected drugs in 2007 (range 11-21 million). 1 Much of the estimated burden of disease attributable to the use of illicit drugs is probably due to blood-borne viral infections through unsafe drug injection. 2 Hepatitis B and C viruses (HBV and HCV, respectively) are even more efficiently spread by this practice than is HIV. 3 About 80% of individuals exposed to HCV develop chronic infection, 4 and 3-11% of people with chronic HCV infection will develop liver cirrhosis within 20 years, 5 with associated risks of liver failure and hepatocellular carcinoma. 6 Transmission of HCV increasingly occurs through injecting drug use, 7 but in many developing countries unsafe medical injections and transfusions are predominant sources of infection. The emergence of injecting drug use is an additional threat in settings where the prevalence of HCV is high (eg, Africa, the Middle East, and southeast Asia).
HBV is highly contagious through parenteral, sexual, and vertical (perinatal transmission) routes. About 5% of adults exposed to HBV develop chronic HBV infection; 4 most of the 350 million chronically infected people worldwide were infected in childhood. 8 Cirrhosis and death because of hepatocellular carcinoma are important sequelae of chronic HBV infection. 9 Despite the higher prevalence and transmissibility of viral hepatitis, the disease has received far less global attention than has HIV. WHO called prevention and control efforts "successful but fragmented...[with no] comprehensive strategy for viral hepatitis". 10 At WHO's 63rd World Health Assembly in May, 2010, a resolution was passed to establish "goals and strategies for disease control, increasing education and promoting screening and treatment" 10 of people infected with HBV and HCV. WHO argues that injecting drug users (IDUs) are a key group that need to be specifically targeted for prevention and treatment of viral hepatitis. 10 For such efforts to be appropriately scaled and targeted, policy makers and health-care professionals need accurate and detailed data for the size of the population at risk, as exist for HIV. 1 There have been no global systematic reviews of HBV prevalence in IDUs. 11 Previous reviews of HCV in this population have been selective in their geographical coverage, 12 have not provided sources or estimation methods, 13 or did not make estimates of population size. 14 Here, we report a systematic search and critical review of the peer-reviewed and grey literature on hepatitis C antibodies (anti-HCV), hepatitis B core antibodies (antiHBc), and hepatitis B surface antigens (HBsAg) in IDUs, showing the best available country-level data, and the first regional and global estimates of the number of IDUs living with HCV and HBV. We do not report estimates of chronic hepatitis A, D, or E viral infection (HAV, HDV, and HEV, respectively). Chronic HAV infection does not occur, and in developing countries most adults are immune, making epidemics uncommon; however, with increased sanitation this epidemiological pattern might change in some populations. 15 HDV has been associated with injecting drug use; however, the extent of the published work on HDV (which needs concurrent HBV for infection to be established) is small and the diversity in prevalence, even in countries with a high prevalence of HBV, makes extrapolation between countries difficult. 16 HEV is enterically transmitted and HEV data for IDUs is scarce.
Methods

Study design and search strategy
We undertook our review in line with the methods outlined by the Global Burden of Disease (GBD) project and complied with PRISMA guidelines relevant to a descriptive review of this nature. 17 Our searches consisted of multiple stages of searches of the peer-reviewed and grey literature, international consultations, and expert critique and review, as undertaken in a previous review of HIV in IDUs. 1 Data from the HCV Synthesis Project 18 were also provided for review and inclusion. The HCV Synthesis Project was a systematic global review of published and unpublished sources containing reports of HCV infection and co-occurring HBV infection in IDUs until 2006. We searched peer-reviewed databases (Medline, Embase, and PsycINFO) of the published work in November, 2010, with search strings developed in consultation with specialist drug and alcohol librarians (see webappendix pp 1-4). We included abstracts published in English but translations were sought for promising non-English papers, and searches were updated in May, 2011.
We searched the grey literature and online databases, including websites of drug surveillance systems, regional harm-reduction networks, and country-specific minis tries of health. Methods to identify and systematically search these sources have been described previously 19, 20 and we have used them in previous systematic reviews. 18 
Figure 1: Systematic review process
In this study, for sources that reported for several years, only the most recent data were extracted. For sources reporting prevalence between sites or samples within a study, the overall report was extracted (individual reports within a study were not). HCV=hepatitis C virus. IDU=injecting drug user. Anti-HCV=hepatitis C antibodies. Anti-HBc=hepatitis B core antibodies. HBsAg=hepatitis B surface antigen. *Sources could contain more than one report (several hepatitis markers, samples, or locations).
that were reported here. Data were received, and clarification sought, until June, 2011.
Data extraction and selection
We catalogued documents with Endnote X4. Figure 1 shows the search process and flow chart. Two authors (PKN and DH) systematically screened search results. Studies in the HCV Synthesis Project 18 database were automatically included. Other references were reviewed if the title or abstract suggested that the document had relevant information about the prevalence of HCV or HBV in IDUs. We reviewed 1125 documents (peer-reviewed and grey literature) in full. Data were regarded as eligible when the number or prevalence of hepatitis-infected IDUs in a country or subnational area were mentioned.
We extracted information about study methods (specimen type, eligibility criteria, recruitment and enrolment dates, and recruitment methods and locations), participant characteristics (age range and sex), and hepatitis reports (number of participants tested, number and proportion of patients who tested positive for anti-HCV, anti-HBc, and HBsAg, and reports broken down by age and sex). Detailed methodological infor mation was used to grade and select studies for inclusion because such study information is thought to strongly influence descriptive methods. 18 Extracted information was initially reviewed by two authors (PKN and DH), and valid reports were included in a Microsoft Access database and reviewed by another author (LD). We graded data as shown in panel 1.
For this analysis, we selected the highest and lowest reports of every seromarker for every country in accordance with the decision rules described in panel 2. These were entered into Microsoft Excel by one author (LD) and independently reviewed by two others (PKN and BMM). Provisional reports were circulated to all authors for review and comment. External checks were made with specific requests to experts in countries if additional data or clarification were needed.
Data for prevalence of viral hepatitis
Existing reports about HCV prevalence in IDUs are based predominantly on serological testing for anti-HCV. A We included studies of HBV if they reported serological testing for HBsAg or anti-HBc. HBsAg testing shows active (either acute or chronic) infection, but about 95% of adults with acute HBV infection will clear the virus, lose HBsAg and develop anti-HBc and hepatitis B surface antibodies (anti-HBs). However, clearance rates for HBV might be lower for IDUs than they are for the general population because more IDUs might become chronically infected; this effect could relate to repeated exposure or lower immunity due to worse health and other viral infections. 21 The presence of anti-HBc shows previous exposure and is a more durable marker than is presence of HBsAg. To clearly establish whether HBV infection was resolved or resulted in immunity, or to establish vaccination-related immunity, the results of more than one test in combination would need to be assessed; however, this duplicity is rarely available in population-scale or other large epidemiological studies.
Data for prevalence of injecting drug use
We obtained prevalence data for injecting drug use and HIV from a previously published systematic review by the Reference Group to the United Nations on HIV and Injecting Drug Use (herein termed the Reference Group review), 1 adhering to international guidelines for systematic reviews, 22 with decision rules and estimates approved by all Reference Group members. During the course of a subsequent review of HIV prevention, treatment, and care for IDUs, updated prevalence data for some countries were submitted to the Reference Group. 23 These data were included in our analysis, together with more recent data for injecting drug use and HIV prevalence reported by EMCDDA and Joint United Nations Programme on HIV/AIDS (UNAIDS). Overall, we included updated estimates of IDU population size for Belarus, Brazil, Croatia, Cyprus, Czech Republic, Greece, Nepal, Philippines, and Ukraine and updated estimates of HIV prevalence for Croatia, Cyprus, Mauritius, Moldova, Norway, Pakistan, Portugal, Sierra Leone, Somalia, Swaziland, Togo, Ukraine, UK, and Zimbabwe.
Statistical analysis
We used MapInfo 10.0 to generate maps of prevalence estimates for injecting drug use and hepatitis in IDUs.
Prevalence of anti-HCV in injecting drug users (%)
Prevalence of anti-HBc in injecting drug users (%) Prevalence of HBsAg in injecting drug users (%) After collation of country-specific estimates, we derived regional and global estimates for 2010. All authors reviewed the estimates, and regional or country-specific queries were made to experts when clarification was needed. Prevalence of injecting drug use was assumed to be the same in 2010 as it was in the year of the estimate. We used UN Population Division estimates to establish population sizes of people aged 15-64 years in 2010. 24 Regional estimates were derived through estimation of regionspecific, weighted estimates of the prevalence of injecting drug use and hepatitis infection and uncertainty bounds, with methods previously endorsed by the Reference Group 1 (webappendix pp 6-8). We grouped regions on the basis of previous UNAIDS categories to ease comparisons with the Reference Group HIV review. 1 We used Microsoft Excel to calculate prevalence estimates.
Role of the funding source
The US National Institutes of Health supported the work of the HCV Synthesis Project, and the HIV department of WHO (Geneva, Switzerland) provided some funds to support our report. Staff from WHO assisted with data collection by circulating requests for data to WHO and other UN agency staff, and helped obtain access to reports We identified no reports of injecting drug use for North Korea. Source documents for all figures listed in tables are shown in webappendix pp 9-16. When more than one year or grade is shown, these are listed in order of the report they refer to (ie, lowest report first). NK=although injecting drug use has been identified or injecting drug use prevalence estimated, no eligible report of HCV or HBV in injecting drug users were located. HCV=hepatitis C virus. HBV=hepatitis B virus. *A systematic review and meta-analysis by Xia and colleagues 45 was not included here as the source documents were in Chinese and could not be verified. In that review, the pooled prevalence was 61·4% (IQR 55·7-67·2) across 53 Chinese and two English language multiregion studies of HCV in injecting drug users in China. †Publication year minus 3 (year of estimate not stated). 
Results
We identified eligible reports on anti-HCV in IDUs for 77 of the 152 countries or territories where injecting drug use has been reported (figure 2, tables 1-5, webappendix pp 9-16); these 77 countries hold 82% of the world's estimated population of IDUs. Anti-HCV prevalence varied greatly: midpoint reports ranged from 9·8% to 97·4% (tables 1-5). 19, 20 Anti-HCV prevalence was 60-80% in IDUs in 25 countries, and 80% or higher in a further 12. The countries with the largest estimated populations of IDUs were China (midpoint estimate 67·0%), Russia (72·5%), and the USA (73·4%; tables 1-3) . No studies were located for Caribbean countries or Pacific Island states and territories (table 3 and table 4) .
HBV exposure (anti-HBc positive) was measured in 43 countries, accounting for 65% of the world's population of IDUs (webappendix p 17). Rates varied widely between countries, from 4·2% in Slovenia to 85·0% in Mexico (tables 1-5). Prevalence of HBsAg was measured in 59 countries, accounting for 73% of the world's population of IDUs ( figure 3, tables 1-5 ). The highest rates of HBsAg were in countries (mostly in Asia) that have endemic HBV in the general population. HBsAg prevalence reports in IDUs varied substantially within countries; for example, prevalence reports of HBsAg ranged from 3·5% to 20·0% in the USA and 3·7% to 30·9% in Iran (table 3  and table 4 ).
Prevalence of anti-HCV in injecting drug users (%)
Prevalence of anti-HBc in injecting drug users (%) Prevalence of HBsAg in injecting drug users (%) 
Table 3: Prevalence of hepatitis C antibodies (anti-HCV), hepatitis B core antibodies (anti-HBc), and hepatitis B surface antigen (HBsAg) in injecting drug users in the Americas
Data quality varied between all three indicators of hepatitis, with only 20 countries having eligible grade A reports (panel 1) for at least one marker, and few of these reports were nationally representative (tables 1-5). In many countries, prevalence reports came from samples from different sites (grade B1). For most countries, we were able to use reports produced since 2000; however, about 25% of countries only had HBV reports from before 2000 (tables 1-5).
After extrapolation to all countries, we estimated that about 10·0 million IDUs (range 6·0-15·2) in 2010 were anti-HCV positive (table 6; a midpoint prevalence of 67·0% in IDUs globally). This value is about 3·5 times larger than the 2·8 million IDUs (range 0·8-6·2 million) who are estimated to be living with HIV (webappendix p 18).
The largest populations of HCV-positive IDUs lived in eastern Europe (2·3 million, range 1·2-3·9) and east and southeast Asia (2·6 million, 1·8-3·6). The three countries with the largest populations of IDUs living with HCV were China (1·6 million, range 1·1-2·2), Russia (1·3 million, range 0·7-2·3), and the USA (1·5 million, range 1·0-2·2).
We estimate that globally in 2010, 1·2 million (range 0·3-2·7) IDUs were HBsAg positive, with an IDU population-weighted global prevalence of 8·4%. The largest populations by region are east Asia and southeast Asia (0·3 million, range 0·1-0·7) and eastern Europe (0·3 million, 0·1-0·5 million). The large ranges around all these estimates shows the uncertainty resulting from varying prevalence between different subpopulations of IDUs and different recruitment settings.
Discussion
Our global systematic review suggested that around 10·0 million IDUs are HCV positive and around 1·2 million are HBsAg positive. Clear geographical differences exist in prevalence. Eastern Europe, east Asia, and southeast Asia have the largest populations of IDUs infected with viral hepatitis.
Notably, the population size estimates we reported refer to the estimated number of current or recent users of injected drugs who were positive for anti-HCV, anti-HBc, or HBsAg, and not people who have ever injected drugs. Many people who inject drugs cease injecting at some point, 25 so our estimations cannot be interpreted as the total number of cases of HCV or HBV attributable to injecting drug use. Because of the limitations in understanding of the natural history of injecting drug use (such as the range in duration of injecting, and the likelihood and timing of resumption after cessation), especially in low-income and middle-income countries, defensible regional and global estimates cannot be made for the number of former IDUs, or concomitantly, the numbers of whom might be positive for anti-HCV, anti-HBc, and HBsAg. An estimate of the burden of chronic viral hepatitis in current IDUs is essential for assessment of secular trends in the risk of infection, the effect (and importance of implementation) of control strategies, and implications for future burden of disease and health-care needs.
Efforts to prevent, treat, and reduce harms related to liver disease in IDUs are essential-especially in situations in which HIV has successfully been prevented or managed-because the large numbers of IDUs 
Table 4: Prevalence of hepatitis C antibodies (anti-HCV), hepatitis B core antibodies (anti-HBc), and hepatitis B surface antigen (HBsAg) in injecting drug users in Oceania
infected with HCV and significant morbidity resulting from this infection mean that the health and economic costs of HCV transmitted by injecting drug use might be as high as (or higher than) those of HIV. Nonetheless, HCV treatment is underused. 10 Part of the reason for this neglect is the high cost, which will remain a substantial barrier to increasing of treatment coverage in lowresource settings until costs are reduced. There is increasing attention on this issue among international groups who are advocating for cost reductions, generic We identified no reports of injecting drug use for Angola, Benin, Botswana, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African Republic, Chad, Comoros, Democratic Republic of Congo, Equatorial Guinea, Eritrea, Ethiopia, The Gambia, Guinea, Guinea-Bissau, Lesotho, Liberia, Madagascar, Mali, Mauritania, Mozambique, Namibia, Niger, Republic of the Congo, Rwanda, São Tomé and Príncipe, Seychelles, and Somalia. Source documents for all figures listed in tables are shown in webappendix pp 9-16. When more than one year or grade is shown, these are listed in order of the report they refer to (ie, lowest report first). NK=although injecting drug use has been identified or injecting drug use prevalence estimated, no eligible report of HCV or HBV in injecting drug users were located. HCV=hepatitis C virus. HBV=hepatitis B virus. UAE=United Arab Emirates. *Publication year minus 3 (year of estimate not stated). Table 5 : Prevalence of hepatitis C antibodies (anti-HCV), hepatitis B core antibodies (anti-HBc), and hepatitis B surface antigen (HBsAg) in injecting drug users in the Middle East and Africa manufacturing, and changes to licensing conditions. 10, 26 Not long ago, the high cost of HIV antiretrovirals similarly prevented access in high prevalence, lowincome countries: in recognition of this barrier, there are growing efforts to bring viral hepatitis treatments into the same (lower cost) access framework as HIV antiretrovirals. 10 Nonetheless, another barrier is the toxic effects of HCV treatment, although a large number of new HCV drugs are in development that will revolutionise HCV treatment in the next few years. 27 More attention needs to be paid to reduction of the effect of other causes of progression of liver disease in people who are chronically infected with viral hepatitis. This attention includes addressing problems of alcohol use, and provision of HAV and HBV vaccination, particularly because liver-related disease will become a main cause of mortality as IDUs get older. 28 Evidence about the effect of needle and syringe programmes 29 and provision of other injection equipment on prevention of HCV infection is scarce, but reduction of risk is paramount, particularly during the period of initiation to injecting when incidence of HCV is highest. 6, 14 The potential for HCV treatment to reduce HCV prevalence in IDU populations and therefore reduce the force of infection acting on susceptible members of these populations has been supported by mathematical modelling. 30 This potential role of HCV treatment in the prevention of HCV transmission in IDU populations warrants further investigation.
Although we noted substantial variability in HBsAg prevalence reports, prevalence typically mirrored the differences in the rate of HBV infection in the general population. In countries with a low-intermediate rate, the prevalence of HBsAg in IDUs was typically less than 10%, whereas in countries with a high rate of HBV infection, prevalence of HBsAg in IDUs was around 10-20% (eg, east Asia and southeast Asia). Because of the high rate of chronic HCV infection in IDUs, HBV infection is particularly likely to show HBV and HCV coinfection, which is associated with more rapid progression of liver disease and attendant mortality; 31 this outcome is similarly the case for co-infection between HIV and viral hepatitis. 32 Effective treatments for chronic HBV infection are available, which reduce progression of liver disease and complications such as hepatocellular carcinoma. 33 However, antiviral therapy for chronic HBV infection is often of indefinite duration, and access to modern, potent drugs with high resistance barriers is restricted in many high-prevalence, low-resource settings. Barriers to accessing treatment and care for chronic HBV infection result in poor outcomes for those affected, and ongoing transmission to susceptible contacts.
Vaccination against HBV must be prioritised for all susceptible IDUs, especially those already infected with HCV. However, selective vaccination programmes against HBV in this group have often been characterised by low uptake and difficulty reaching the most at-risk individuals. 34 A substantial reduction in the burden of HBV infection in IDUs is expected in countries with universal infant vaccination programmes, once these individuals reach the age at which acquisition of HBV through injecting drug use is most common. Correctional facilities provide one opportunity to vaccinate, treat, and reduce the transmission of viral hepatitis in a population with high rates of injecting drug use, HBV, and HCV, many of whom cycle in and out of the community. 35, 36 There are several key limitations to the existing data. One issue concerns the way in which HCV and HBV infection are measured and reported between studies: reporting of data was typically done on the basis of only one (or perhaps two) markers, making estimates of the true prevalence of chronic HBV and HCV difficult. Without the measurement and reporting of several markers (anti-HCV plus HCV RNA PCR, or HBsAg plus anti-HBc, and ideally anti-HBs) more accurate estimation of chronic infection, past infection, susceptibility or immunity is not possible. For HCV, we estimated the number of present IDUs who were anti-HCV positive; however, this assessment is not a measure of total chronic HCV infection but rather HCV exposure in IDUs, because a minority (~20%) of those infected with HCV (who would test positive for anti-HCV) will probably clear the virus. 4 For HBsAg, we noted wide ranges in reports that met inclusion criteria. Furthermore, if anti-HBc was not reported, assessment of the proportion of individuals who were positive for HBsAg, acutely infected, and within the window before anti-HBc seroconversion was not possible. Future studies should include both markers to allow a more accurate understanding of study results. Additional sample details, including country of birth and ethnicity, would also assist inter pretation. 37 An additional limitation of the existing data is the scarcity of data for the age range of samples and duration of drug-injecting history and therefore time of raised exposure to viral hepatitis, which would permit more accurate understanding of varying prevalence of both HCV and HBV between samples. Our reliance on older studies, with less accurate serological testing techniques and small sample sizes, and those undertaken in countries where laboratory capacity is low, increases uncertainty about the validity of both HCV and HBV reports.
A final issue relates to the representativeness of samples of people who inject drugs. Some studies of HBV and HCV recruited participants who had ever injected drugs, whereas others recruited those who had injected in the past year or were current users. Studies also recruited from various locations, including prisons, drug-treatment centres, outpatient clinics, and other medical settings, in which IDUs might differ in their risk behaviour and exposure to viral hepatitis. Moreover, convenience sampling is most often used, so samples All figures rounded to nearest 500 people; global figure totalled from regional estimates prior to rounding. 2010 UN population division estimates were used to derive 2010 estimates of population sizes of IDUs. IDU=injecting drug user. ERIP=estimated regional population of IDUs. *Insufficient data to produce a region-specific estimate for populations of IDUs in this region; countries in this region were still included in global estimates. †Numbers of sub-Saharan African IDUs and derived population estimates should be viewed with caution because injecting drug user prevalence estimates were derived from three countries in the region (South Africa, Mauritius, and Kenya); the estimated range of IDUs was derived by applying the regional observed error (the large error band emphasises the uncertainty around these estimates). possibly do not represent the IDU population from which they are drawn. Data were also typically subnational and from a small number of locations that might or might not be representative of the epidemic nationally, particularly in larger countries where there might be much geographical variation, potentially restricting national representativeness. We have used the same methods as in our previous reports. 1 As in these previous investigations, limitations of this report included the concentration of peer-reviewed data from high-income countries, the small team who undertook the analysis, and the potential for papers in languages other than English to be overlooked. We attempted to address these limitations by consulting widely with experts and stakeholders, seeking unpublished reports and verifying the data from reports included, and enlisting the support of UN and other agencies, who helped gain access to data and contact with relevant in-country personnel.
The public-health response to blood-borne virus transmission in IDUs has mainly centred on HIV. Maintenance and strengthening of the response to HIV in IDUs remains crucial, but the significance of viral hepatitis needs to receive greater attention than it does at present. Investment in, and development of, comprehensive and effective strategies to prevent the transmission of viral hepatitis and reduce resultant morbidity and mortality in IDUs are urgently required. The viral hepatitis resolution of the 63rd World Health Assembly 10 requested that the Director General of WHO collaborate with all relevant stakeholders in supporting surveillance, preven tion, and treatment goals, especially in developing countries. Policies and strategies for viral hepatitis need to include IDUs, who are at increased risk and often have poorer access to services than do the general population. Our report provides estimates of the scale of this problem at country, regional, and global scales, and the findings should inform efforts to accurately scale and appropriately target the response.
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Hepatitis in drug users: time for attention, time for action
In place of saints' days or public holidays, public health practitioners celebrate disease days: World Cancer Day in February, 1 Stroke Day in October, 2 and World AIDS Day on Dec 1. 3 The main reason for these days is to raise awareness, a key part of which is the presentation of descriptive statistics: without intervention, 84 million people will die of cancer between 2005 and 2015; 1 every 6 s someone will die from stroke; 2 and 33 million people are living with HIV. 3 In The Lancet, Paul Nelson and colleagues 4 review 4386 peer-reviewed sources and 1019 grey literature sources to estimate-at national, regional, and global scales-prevalence and population estimates for hepatitis B and C in injecting drug users (IDUs). The investigators provide the requisite bold statistics: 10 million IDUs might be positive for hepatitis C antibodies and more than 80% of IDUs in 12 countries are estimated to be infected. More than 6 million IDUs might be positive for hepatitis B core antibodies. The investigators do not estimate the burden of death and disease from these infections, but it is likely to be substantial: more than 1·5 million deaths occur every year from acute hepatitis B and C infections, hepatocellular carcinoma, and cirrhosis. 5 July 28 is World Hepatitis Day, and the article by Nelson and colleagues 4 forms part of the efforts to raise awareness about this disease. While focusing attention on hepatitis is a challenge generally, mobilisation of action to address the disease in drug users is even more difficult.
Drug users around the world face stigma, discrimination, mistreatment, and the systematic violation of their human rights. 6 Harm-reduction strategies that, in addition to prevention of HIV infection, could help to reduce hepatitis B and C transmission are widely underfunded or blocked by local or national governments altogether. In June, 2011, the United Nations General Assembly feebly called on nations to give "consideration, as appropriate" to implementation and expansion of harm-reduction programmes. 7 Not surprisingly, countries that do not find drug users worthy of consideration often find harm reduction inappropriate. 8 Through country-by-country estimates, Nelson and colleagues provide an opportunity to examine striking disparities in rates of hepatitis B and C. Why is the prevalence of hepatitis C antibodies in IDUs in Hungary 23%, whereas it is about 90% in Estonia or Lithuania and 73% in Russia? Why do 85% of IDUs in Mexico have hepatitis B core antibodies compared with 20% of IDUs in Uruguay? These differences could be due to the limitations of the data: despite thousands of studies reviewed, grade A reports (ie, a multisite seroprevalence study with several sample types for at least one hepatitis marker) were only available for 20 of the 77 countries for which any data were available, and few studies provided truly national estimates. 4 However, the differences may also show trends and patterns of drug use, or important differences in state policies and investment in harm reduction. Large between-country variations emphasise how high rates of hepatitis B, hepatitis C, or HIV infection in drug users are not inevitable. 9 Moreover, the estimates provide a powerful means for health and human rights advocates to question government officials in countries with high prevalences, and to caution governments in countries with low prevalences about the potential costs (human and economic) of failing to put in place, or sustain, effective, rights-based policies.
Nelson and colleagues 4 conclude that improved recogni tion of hepatitis in IDUs and development of comprehensive and effective strategies are needed. No doubt this is true, to some extent. However, the history of HIV in IDUs shows that much more than awareness 
